[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR200102779T2 - Antikor ve kemokin yapìlarìnìn oto baĞìçìklìk hastalìklarìnìn tedavisinde kullanìmì - Google Patents

Antikor ve kemokin yapìlarìnìn oto baĞìçìklìk hastalìklarìnìn tedavisinde kullanìmì

Info

Publication number
TR200102779T2
TR200102779T2 TR2001/02779T TR200102779T TR200102779T2 TR 200102779 T2 TR200102779 T2 TR 200102779T2 TR 2001/02779 T TR2001/02779 T TR 2001/02779T TR 200102779 T TR200102779 T TR 200102779T TR 200102779 T2 TR200102779 T2 TR 200102779T2
Authority
TR
Turkey
Prior art keywords
treatment
chemokine
structures
antibody
diseases
Prior art date
Application number
TR2001/02779T
Other languages
English (en)
Inventor
Mack Matthias
Schl�Ndorff Detlef
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of TR200102779T2 publication Critical patent/TR200102779T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluç, kemokin al c lar na karç eksprime eden hücrelere, özellikle de kemokin al c s CCR5' e karç eksprime eden monozit/makrofajlar ve CCR5+ T hücrelerine karç olan antikor ve kemokin yap lar yla ilgilidir. Öte yandan bu buluç öz baG ç kl k hastal klar n n ve alerjik hastal klar n tedavisi, özellikle de kronik olarak iltihaplanan eklem hastal klar n n tedavisine yönelik olarak antikor ve kemokin yap lar n n, kemokin al c lar na karç eksprime eden hücrelerin imhas nda kullan lmas yla ilgilidir. Buluçun anlay ç ndaki antikor ve kemokin yap lar sayesinde kemokin al c lar na karç eksprime eden hücrelerin seçici bir çekilde de azalt lmas mümkün olduGu için öz baG ç kl k hastal klar nda baG ç kl k sistemini bask layan bir tedavi mümkün olmaktad r.
TR2001/02779T 1999-03-11 2000-03-10 Antikor ve kemokin yapìlarìnìn oto baĞìçìklìk hastalìklarìnìn tedavisinde kullanìmì TR200102779T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19910891 1999-03-11

Publications (1)

Publication Number Publication Date
TR200102779T2 true TR200102779T2 (tr) 2002-03-21

Family

ID=7900625

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02779T TR200102779T2 (tr) 1999-03-11 2000-03-10 Antikor ve kemokin yapìlarìnìn oto baĞìçìklìk hastalìklarìnìn tedavisinde kullanìmì

Country Status (15)

Country Link
EP (1) EP1161456B1 (tr)
JP (1) JP2002540771A (tr)
CN (1) CN1345336A (tr)
AT (1) ATE286074T1 (tr)
AU (1) AU4104700A (tr)
CA (1) CA2366713A1 (tr)
CZ (1) CZ20013270A3 (tr)
DE (1) DE50009113D1 (tr)
ES (1) ES2233359T3 (tr)
HU (1) HUP0200484A2 (tr)
IL (1) IL145335A0 (tr)
NO (1) NO316916B1 (tr)
SK (1) SK12782001A3 (tr)
TR (1) TR200102779T2 (tr)
WO (1) WO2000053633A2 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
EP1317284A2 (en) * 2000-09-08 2003-06-11 Micromet AG Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
DE60203324T2 (de) * 2001-12-21 2006-04-06 Micromet Ag Einzelne und duale anti-cd4-rantes chemokin/zytokin konstrukte
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ccr5 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2074147B1 (en) 2006-09-29 2012-03-21 F. Hoffmann-La Roche AG Antibodies against ccr5 and uses thereof
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
AR084053A1 (es) 2010-11-30 2013-04-17 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
ES2900898T3 (es) 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Anticuerpos biespecíficos inmunoactivadores
AU2015260230A1 (en) 2014-05-13 2016-11-17 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
ZA985542B (en) * 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage

Also Published As

Publication number Publication date
CZ20013270A3 (cs) 2002-02-13
ES2233359T3 (es) 2005-06-16
DE50009113D1 (de) 2005-02-03
NO20014346L (no) 2001-09-27
WO2000053633A3 (de) 2000-11-16
WO2000053633A2 (de) 2000-09-14
SK12782001A3 (sk) 2002-03-05
NO20014346D0 (no) 2001-09-06
EP1161456B1 (de) 2004-12-29
NO316916B1 (no) 2004-06-21
CA2366713A1 (en) 2000-09-14
HUP0200484A2 (en) 2002-06-29
AU4104700A (en) 2000-09-28
ATE286074T1 (de) 2005-01-15
EP1161456A2 (de) 2001-12-12
JP2002540771A (ja) 2002-12-03
IL145335A0 (en) 2002-06-30
CN1345336A (zh) 2002-04-17

Similar Documents

Publication Publication Date Title
TR200102779T2 (tr) Antikor ve kemokin yapìlarìnìn oto baĞìçìklìk hastalìklarìnìn tedavisinde kullanìmì
DE69021456D1 (de) Monoklonale Antikörper gegen aktivierte endotheliale Zellen.
PT1041967E (pt) Microparticulas e o seu uso terapeutico ou diagnostico
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
DK0735818T3 (da) Makrofag-inflammatoriske proteiner MIP-3, Mip-4 og Mip-1gamma
DE3886760D1 (de) Monoklonale antikörper gegen menschliche interleukin-4 und die sie erzeugenden hybridomen.
DE68925226D1 (de) Monoklonale Antikörper
ATE317852T1 (de) Pollen allergene
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
DK0496818T3 (da) IgA-receptor-specifikt monoklonalt antistof
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
DE3879085D1 (de) Snrnp-a-antigen und fragmente davon.
FR2759701B1 (fr) Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
NO177463C (no) STLV-III-beslektede polypeptider, diagnostiske prövesett og in vitro analysefremgangsmåte for påvisning av anti-HIV-2-antistoffer i kroppsvæskepröve
AU641736B2 (en) Delivery of agents
DK0491713T3 (da) Rubella El-peptider og C-peptider
EA199800959A1 (ru) ПРИМЕНЕНИЕ ГЕНЕТИЧЕСКОЙ МОДИФИКАЦИИ В ГЕНЕ b3- СУБЪЕДИНИЦЫ ЧЕЛОВЕЧЕСКОГО G-ПРОТЕИНА ДЛЯ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ
CA2134080A1 (en) Natural humain igm antibodies
NO972046L (no) Antistoff mot allogene og xenogene proteiner, deres bruk i diagnose og terapi samt fremgangsmåter for bestemmelse av slike
ITRM920591A1 (it) Piezomembrana vincolata al centro e suo impiego per la realizzazione di avvisatore acustico.
Reddy Binding between Pseudomonas aeruginosa adhesins and human salivary, tracheobronchial and nasopharyngeal mucins
DE68925202D1 (de) HIV-2-EHO-Retrovirus-Proteine und -Glycoproteine, Antikörper gegen sie, Verwendung für diagnostische Zwecke
IT8721455A0 (it) Composizioni farmaceutiche per la terapia di stati fisiopatologici ad accresciuto catabolismo proteico.